The FDA approved Tzield for stage 3 type 1 diabetes, and the therapy was given to children in Canada for the first time. Research also advanced on engineered islets and stem-cell treatments.
Trump’s Most Favoured Nation drug pricing plan would tie some U.S. drug prices to lower foreign prices. The source articles say the policy could delay launches in Canada, raise Canadian prices and affect R&D decisions.
Canada's Drug Agency issued a draft recommendation against public drug plan coverage for lecanemab, an Alzheimer's treatment conditionally approved by Health Canada in October 2025, citing cost concerns despite the drug's ability to slow cognitive decline.
